CLSN
Celsion Corporation [CLSN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CLSN Stock Summary
In the News
CLSN Financial details
Company Rating
-
Market Cap
14.47M
Income
-86.41M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
29
Optionable
No
Shortable
Yes
Earnings
29 Mar 2023
P/E
-0.22
Forward P/E
-
PEG
-0.02
P/S
50.38
P/B
0.1
P/C
-
P/FCF
-0.46
Quick Ratio
6.12
Current Ratio
6.52
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-10.25
EPS next Y
-
EPS next Q
-
EPS this Y
-57.06%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-28.53%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
40.54%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-33%
ROE
-46%
ROC
-0.2%
Gross Margin
100%
Oper. Margin
-9413%
Profit Margin
-17015%
Payout
-291%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
-
52W High
-
52W Low
-
RSI
4
Rel Volume
-
Avg Volume
-
Volume
56.81K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
2.25649
-
-
Volatility
0.25%, 0.25%
Prev Close
34.25%
Price
1.9466
Change
37.08%
Company Profile
- Market Capitalization 14.47M
- Employee 29
- CEO Michael Tardugno
- Headquarters Lawrence Township,NEW JERSEY,US
- IPO Date 1993-10-27
-
Website
https://celsion.com 
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
